POSITION PAPER| Volume 20, ISSUE 12, P1486-1494, December 2018

Proceedings of the first academic symposium on developing, qualifying and operating a cell and gene therapy manufacturing facility

Published:October 27, 2018DOI:


      A significant portion of the more than 1000 candidate cell and gene therapy products currently under clinical investigation ( are born out of academic research centers affiliated with universities, hospitals and non-profit research institutions. Supporting these efforts are myriad academic clinical materials production facilities with more than 40 such facilities currently operational in the United States alone. In March 2018, Stanford University's Laboratory for Cell and Gene Therapy held a symposium with the leaders and staff of more than 25 similar facilities to discuss the collective experience in developing, qualifying and operating cell and gene therapy manufacturing facilities according to current Good Manufacturing Practices. Topics included facility design, construction, staffing and operations and compliance. Leaders from several institutions gave overviews of the history of development of the facilities and discussed challenges and opportunities they had experienced over the past 10–20 years of operations. Working sessions were also held to discuss specific aspects of Process Development, Manufacturing, Quality Systems, Regulatory Affairs and Business Development with all participants contributing to the discussions. We summarize here the findings of this inaugural meeting with an emphasis on best practices and suggested guidelines for operations.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Lipsitz Y.Y.
        • Milligan W.D.
        • Fitzpatrick I.
        • et al.
        A roadmap for cost-of-goods planning to guide economic production of cell therapy products.
        Cytotherapy. 2017; 19: 1383-1391
        • Hourd P.
        • Chandra A.
        • Alvey D.
        • et al.
        Qualification of academic facilities for small-scale automated manufacture of autologous cell-based products.
        Regen Med. 2014; 9: 799-815
        • Sheu J.
        • Klassen H.
        • Bauer G.
        Cellular manufacturing for clinical applications.
        Dev Ophthalmol. 2014; 53: 178-188
        • Alici E.
        • Blomberg P.
        GMP facilities for manufacturing of advanced therapy medicinal products for clinical trials: an overview for clinical researchers.
        Curr Gene Ther. 2010; 10: 508-515
        • Avgoustiniatos E.S.
        • Hering B.J.
        • Rozak P.R.
        • et al.
        Commercially available gas-permeable cell culture bags may not prevent anoxia in cultured or shipped islets.
        Transplant Proc. 2008; 40: 395-400
        • Dave H.
        • Luo M.
        • Blaney J.W.
        • et al.
        Toward a Rapid Production of Multivirus-Specific T Cells Targeting BKV, Adenovirus, CMV, and EBV from Umbilical Cord Blood.
        Mol Ther Methods Clin Dev. 2017; 5: 13-21
        • Zhu F.
        • Shah N.
        • Xu H.
        • Schneider D.
        • et al.
        Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center.
        Cytotherapy. 2018; 20: 394-406
        • Kloss S.
        • Oberschmidt O.
        • Morgan M.
        • et al.
        Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
        Hum Gene Ther. 2017; 28: 897-913
        • Mock U.
        • Nickolay L.
        • Philip B.
        • et al.
        Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS prodigy.
        Cytotherapy. 2016; 18: 1002-1011
        • Chisholm J.
        • Bhatt S.
        • Chaboureau A.
        • Viswanathan S.
        Strategy for an abbreviated in-house qualification of a commercially available Rapid Microbiology Method (RMM) for canadian regulatory approval.
        Cytotherapy. 2017; 19: 1529-1536
        • Murray L.
        • McGowan N.
        • Fleming J.
        • Bailey L.
        Use of the BacT/alert system for rapid detection of microbial contamination in a pilot study using pancreatic islet cell products.
        J Clin Microbiol. 2014; 52: 3769-3771
        • Jimenez L.
        • Rana N.
        • Amalraj J.
        • Walker K.
        • Travers K.
        Validation of the BacT/ALERT(R) 3D System for Rapid Sterility Testing of Biopharmaceutical Samples.
        PDA J Pharm Sci Technol. 2012; 66: 38-54
        • Skrdlant L.M.
        • Armstrong R.J.
        • Keidaisch B.M.
        • Lorente M.F.
        • DiGiusto D.L.
        Detection of Replication Competent Lentivirus Using a qPCR Assay for VSV-G.
        Mol Ther Methods Clin Dev. 2018; 8: 1-7
        • Cornetta K.
        • Duffy L.
        • Turtle C.J.
        • et al.
        Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products.
        Mol Ther. 2018; 26: 280-288
        • Russom D.
        • Ahmed A.
        • Gonzalez N.
        • Alvarnas J.
        • DiGiusto D.
        Implementation of a configurable laboratory information management system for use in cellular process development and manufacturing.
        Cytotherapy. 2012; 14: 114-121
        • Arslan O.
        Hemosoft: a new software for blood bank and apheresis management.
        Transfus Apher Sci. 2004; 30: 193-196
        • Aandahl G.S.
        • Knutsen T.R.
        • Nafstad K.
        Implementation of ISBT 128, a quality system, a standardized bar code labeling of blood products worldwide, electronic transfusion pathway: four years of experience in Norway.
        Transfusion. 2007; 47: 1674-1678